Lyell Immunopharma:Pivotal试验数据更新预计2026年下半年公布,BLA提交计划于2027年下半年进行

美股速递
Jun 13

Lyell Immunopharma公司宣布,其关键性临床试验的数据更新预计将在2026年下半年获得。此外,公司计划于2027年下半年提交生物制品许可申请(BLA)。这一时间表标志着该公司在推进其研发管线方面的重要节点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10